Recent news on Peginterferon Alfa-2B

Celgosivir with Peginterferon and Ribavirin in Chronic Hepatitis C  -  May 21, 2007
SpiritIndia,Non-responder patient study results also demonstrate an improved mean decrease in HCV viral loads when celgosivir is added to peginterferon alfa-2b and

Approvals: Herceptin, Reyataz, and Peg-Intron  -  May 21, 2007
Medscape (subscription)On April 5, the Chinese State Food and Drug Administration approved a new indication for peginterferon alfa-2b injection (Peg-Intron, Schering-Plough

Committee for Medicinal Products for Human Use Post-authorisation ...  -  Apr 27, 2007
PharmaLive.com (press release),Adult patients: Rebetol is indicated, in combination with peginterferon alfa-2b, for the treatment of adult patients with chronic hepatitis C,

Schering-Plough Announces Hepatitis C Data Presentations at ...  -  May 18, 2007
PR Newswire (press release),Room 206 Phase II Study of celgosivir in combination with Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients;

Meeting Highlights From The Committee For Medicinal Products For ...  -  Apr 27, 2007
Medical News Today (press release),Pegintron and Viraferonpeg (peginterferon alfa-2b), from Schering Plough Europe, to extend the indication of these medicines to include the treatment of

Data Suggest that Pegasys May be an Option in Hepatitis C Patients ...  -  May 21, 2007
PharmaLive.com (press release),...that all patients who discontinued treatment with Peg-Intron(R) (peginterferon alfa-2b) and ribavirin due to adverse events within the first 12 weeks,

Schering-Plough Announces Hepatitis C Data Presentations At ...  -  May 19, 2007
Medical News Today (press release),A total of 20 oral and poster presentations on clinical studies with Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b)

MIGENIX to Present Celgosivir Phase II Hepatitis C Results at ...  -  May 18, 2007
CNW Telbec (Communiqués de presse),The presentation entitled: "Phase II Study of Celgosivir in Combination with Peginterferon alfa-2b and Ribavirin in Chronic Hepatitis C Genotype-1

New Clinical Study Results Indicate Higher Early Virologic ...  -  Apr 11, 2007
CNW Telbec (Communiqués de presse),The presentation entitled: "Phase II Proof of Concept Study of Celgosivir in Combination with Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C

Schering-Plough Addresses Major Milestones and Challenges in ...  -  Apr 11, 2007
PharmaLive.com (press release),Peginterferon Alfa-2b and Ribavirin for 14 or 24 Weeks in Patients with HCV Genotype 2 or 3 and Rapid Virological Response, The North-C Trial.

Schering-Plough Addresses Major Milestones and Challenges in ...  -  Apr 10, 2007
PR Newswire (press release),Key Data Presentations at EASL PEGINTRON Peginterferon Alfa-2b and Ribavirin for 14 or 24 Weeks in Patients with HCV Genotype 2 or 3 and Rapid Virological

Additional Preclinical Data Presented on Valopicitabine Combined ...  -  Apr 12, 2007
PR Newswire (press release),2 Manns, M. Peginterferon Alfa-2b Plus Ribavirin Compared with Interferon Alfa-2b Plus Ribavirin for Initial Treatment of Chronic Hepatitis C: A Randomized

PEGINTRON(TM) Approved In China For Treating Chronic Hepatitis B  -  Apr 8, 2007
Medical News Today (press release),Schering-Plough Corporation (NYSE: SGP) today announced that PEGINTRON(TM) (peginterferon alfa-2b) has been approved by the Chinese State Food and Drug

PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B  -  Apr 5, 2007
Earthtimes.orgKENILWORTH, NJ, April 5 -- Schering-Plough Corporation today announced that PEGINTRON(TM) (peginterferon alfa-2b) has been approved by the Chinese State

PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B  -  Apr 5, 2007
PR Newswire (press release),KENILWORTH, NJ, April 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that PEGINTRON(TM) (peginterferon alfa-2b) has

Additional Preclinical Data Presented on Valopicitabine Combined ...  -  Apr 12, 2007
PharmaLive.com (press release),Hepatitis C Virus Infection. New England Journal of Medicine 2002. 2 Manns, M. Peginterferon Alfa-2b Plus Ribavirin Compared with Interferon.

MIGENIX Reports Third Quarter Fiscal Year 2007 Financial Results  -  Apr 4, 2007
Drug Newswire (press release),...celgosivir triple combination (celgosivir plus peginterferon alfa-2b plus ribavirin) as compared to the active control treatment (peginterferon alfa-2b

SP delivers again, beating forecasts  -  Apr 20, 2007
Pharma Times (subscription),Among other products boosting revenue was the antibiotic Avelox (moxifloxacin), up 43% to $115 million, and Pegintron (peginterferon alfa-2b) for hepatitis

Pegintron Approved in China for Treating Chronic Hepatitis B  -  Apr 5, 2007
PharmaLive.com (press release),KENILWORTH, NJ, April 05, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that PEGINTRON(TM) (peginterferon alfa-2b) has been

Schering-Plough Wins Chinese Approval For PEGINTRON For Treatment ...  -  Apr 5, 2007
Trading Markets,...(SGP | charts | news | PowerRating) revealed that PEGINTRON or peginterferon alfa-2b has been approved by the Chinese State Food and Drug Administration for

Milestones, Challenges In Treatment Of Patients With Chronic ...  -  Apr 11, 2007
eMaxHealth.com,Among these are several studies with PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin) combination therapy, a current standard of care in the

Schering-Plough Reports Financial Results for First Quarter of 2007  -  Apr 19, 2007
PR Newswire (press release),...(Announced April 4) -- Gained approval from the Chinese State Food and Drug Administration for PEGINTRON (peginterferon alfa-2b) for the treatment of

MIGENIX Receives New Clinical Study Results Indicating Higher ...  -  Apr 11, 2007
Trading Markets,...over 12 weeks of treatment, the efficacy, safety, and tolerability of celgosivir in combination with peginterferon alfa-2b, with or without ribavirin,

Biotech In Review: Bidding War Erupts For Biosite  -  Apr 7, 2007
Seeking Alpha,There are 120 million chronic carriers of the disease and 330000 deaths annually, due to complications from hepatitis B. Pegintron, or peginterferon alfa-2b

SFDA Approves Schering-Plough's Pegintron For Chronic Hepatitis B ...  -  Apr 5, 2007
Trading Markets,State Food and Drug Administration or SFDA has approved its Pegintron or peginterferon alfa-2b for the treatment of patients with chronic hepatitis B.

MIGENIX Reports Third Quarter Fiscal Year 2007 Financial Results  -  Mar 13, 2007
CNW Telbec (Communiqués de presse),...celgosivir triple combination (celgosivir plus peginterferon alfa-2b plus ribavirin) as compared to the active control treatment (peginterferon alfa-2b

MIGENIX provides update on license-option agreement with Schering ...  -  Feb 6, 2007
CNW Telbec (Communiqués de presse),Material Transfer and License Option Agreement Under the terms of the Agreement, Schering supplied PEGETRON(TM) (peginterferon alfa-2b powder for solution

Migenix hepatitis study samples require retesting  -  Feb 6, 2007
Pharmaceutical Business ReviewSchering-Plough was supplying Pegetron (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) as well as other services for the trial as

Migenix Provides Update on License-Option Agreement with Schering ...  -  Feb 6, 2007
PharmaLive.com (press release),Under the terms of the Agreement, Schering supplied PEGETRON(TM) (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) as well as

FDA Safety Changes: Keppra, Naropin, Rebetol  -  Dec 22, 2006
Medscape (subscription)It is also indicated for use in conjunction with recombinant peginterferon alfa-2b injection for the treatment of HCV in patients aged 18 years and older

FDA Safety Changes: Keppra, Naropin, Rebetol  -  Dec 22, 2006
Medscape (subscription)It is also indicated for use in conjunction with recombinant peginterferon alfa-2b injection for the treatment of HCV in patients aged 18 years and older

MIGENIX Reports Second Quarter Fiscal Year 2007 Financial Results  -  Dec 14, 2006
Drug Newswire (press release),The agreement with Schering provides for (a) the supply of PEGETRON(R) (peginterferon alfa-2b powder plus ribavirin), (b) certain technical and laboratory

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)Pearlman B, Ehleben C, Saifee S. Improved virologic response rates with treatment extension to 72 weeks of peginterferon alfa-2b plus weight-based ribavirin

Results of Peginterferon Alfa-2b and Ribavirin Study in Retreating ...  Oct 30, 2006
Schering-Plough today reported data from EPIC3, a large ongoing clinical study, showing that retreatment with PEG-Intron(R) (peginterferon alfa-2b) and Rebetol ... -DG News Celgosivir Combination Therapy Demonstrates Positive Clinical ...  Nov 6, 2006
Patients were randomized into three treatment arms: (i) celgosivir plus peginterferon alfa-2b plus ribavirin ("triple combination"); (ii) celgosivir plus ... -Yahoo! News (press release) New Data from Largest US Hepatitis C Trial Provide Insights Into ...  Oct 31, 2006
...trial, the largest hepatitis C study ever conducted in US patients, provide important insights into optimizing treatment with peginterferon alfa-2b (PEG-Intron ... -DG News Schering-Plough Highlights Hepatitis C Clinical Data Presentations ...  Oct 24, 2006
FirstCall/ -- More than 50 data presentations involving Schering-Plough's hepatitis products, including PEG- INTRON(R) (peginterferon alfa-2b) and REBETOL(R ... -PR Newswire (press release), Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating ...  Oct 27, 2006
Schering-Plough today reported data from EPIC3, a large ongoing clinical study, showing that retreatment with PEG-INTRON® (peginterferon alfa-2b) and REBETOL ... -Yahoo! News (press release) Results of PEGINTRON(R) and REBETOL(R) Study in Retreating ...  Oct 27, 2006
Schering-Plough today reported data from EPIC3, a large ongoing clinicalstudy, showing that retreatment with PEGINTRON(R) (peginterferon alfa-2b) andREBETOL(R ... -Earthtimes.org Sustained Virological Response Achieved With Weight-Based ...  Nov 1, 2006
...[Presentation title: An Interim Analysis of the Canadian POWeR Program (Peginterferon alfa-2b Prospective Optimal Weight-Based Dosing Response): Consistent SVR ... -DG News Schering-Plough Highlights Hepatitis C Presentations at the ...  Oct 24, 2006
KENILWORTH, NJ -- More than 50 data presentations involving Schering-Plough's hepatitis products, including PEG- INTRON® (peginterferon alfa-2b) and REBETOL ... -EndoNurse, Schering hep C drug combo works in obese  Oct 30, 2006
...said a recent review of data from the WIN-R trial, involving more than 4,900 patients, suggests the combination of Schering's peginterferon alfa-2b -- sold as ... -United Press International "A La Carte" Therapy More Cost-Effective Than Standard Combination ...  Oct 30, 2006
The researchers constructed a budgetary impact model using a decision-tree analysis to compare (a) peginterferon alfa-2b and weight-based ribavirin for 24 ... -DG News Market Report -- In Play (SGP)  Oct 27, 2006
...virologic response Co reported data from EPIC3, a large ongoing clinical study, showing that retreatment with PEG-INTRON (peginterferon alfa-2b) and REBETOL ... -MSN Money MIGENIX Reports First Quarter Fiscal Year 2007 Financial Results  Sep 14, 2006
...of efficacy and safety in 57 non-responder patients randomly assigned to one of three treatment arms: (i) celgosivir plus peginterferon alfa-2b plus ribavirin ... -Yahoo! News

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)Pearlman B, Ehleben C, Saifee S. Improved virologic response rates with treatment extension to 72 weeks of peginterferon alfa-2b plus weight-based ribavirin

Barriers to the treatment of deadly timebomb disease removed  Aug 23, 2006
Pegasys combination therapy was recommended as first line treatment along with peginterferon alfa-2b combination therapy, within their respective licensed ... -Response Source

Schering-Plough Corporation Mourns Death of Jonathan R. ...  Jul 31, 2006
...pharmaceutical products, including INTRON® A (interferon alfa-2b recombinant), an anticancer/antiviral therapy; PEG-INTRON® (peginterferon alfa-2b), a longer ... -Yahoo! News

Schering-Plough Corporation Mourns Death of Jonathan R. ...  Jul 31, 2006
...products, including INTRON(R) A (interferon alfa-2b recombinant), an anticancer/antiviral therapy; PEG-INTRON(R) (peginterferon alfa-2b), a longer- acting form ... -PR Newswire

MIGENIX Reports Fourth Quarter and Fiscal Year 2006 Financial ...  Jul 13, 2006
...of efficacy and safety in 57 non-responder patients randomly assigned to one of three treatment arms: (i) celgosivir plus peginterferon alfa-2b plus ribavirin ... -Yahoo! News

Jonathan R. Spicehandler, MD Retires From Schering-Plough  Jun 30, 2006
...significant products, including INTRON® A (interferon alfa-2b recombinant), an anticancer/antiviral therapy; PEG-INTRON® (peginterferon alfa-2b), a longer ... -Yahoo! News

Schering-Plough to Expand Its Presence in Latin America ...  Jun 21, 2006
Limitada will assume commercial responsibility for Schering-Plough specialty care products, including PEG-INTRON(R) (peginterferon alfa-2b), TEMODAL(R ... -Finanzen.net



MIGENIX Receives Approval for MX-3253 Phase II Combination Viral ...  16 May 2006
The study is designed to demonstrate improved antiviral activity when celgosivir is used in combination with peginterferon alfa-2b, with or without ribavirin ... - Yahoo! News

EU Label Change for Intron A (Interferon Alfa-2b) Incorporates ...  Apr 26, 2006
Schering-Plough also markets a longer-acting, once-weekly pegylated version of interferon alfa-2b called PEG-Intron (peginterferon alfa-2b), for use as ... - DG News

EU Label Change for INTRON(R) A (interferon alfa-2b) Incorporates ...  Apr 25, 2006
Schering-Plough also markets a longer-acting, once-weekly pegylated version of interferon alfa-2b called PEGINTRON (peginterferon alfa-2b), for use as ... - Finanzen.net

MIGENIX to Present at Several Upcoming Investor and Scientific ...  May 2, 2006
I inhibitor for the treatment of chronic hepatitis C virus (HCV) infections currently enrolling patients in combination with peginterferon alfa-2b; with and ... - Yahoo! News

WIN-R Study Demonstrates Efficacy of Shorter PEG-Intron and ...  Apr 28, 2006
...patients infected with hepatitis C virus (HCV) genotype 2 or 3, a shorter, 24-week course of therapy with PEG-Intron(R) (peginterferon alfa-2b) in combination ... - DG News

Schering-Plough's shorter dose hepatitis regimen shows promise  May 2, 2006
..."These findings are important because they confirm the effectiveness of a shorter course of peginterferon alfa-2b and ribavirin combination therapy for ... - Pharmaceutical Business Review

Schering-Plough Advances Development of Hepatitis Capsules  Apr 21, 2006
SCH 503034 is being evaluated in a large phase II study in combination with peg-intron (peginterferon alfa-2b) for the treatment of patients chronically ... - International News Service

Schering-Plough Provides Update on Oral HCV Protease Inhibitor SCH ...  Apr 19, 2006
SCH 503034 is being evaluated in a large Phase II study in combination with PEG-INTRON® (peginterferon alfa-2b) for the treatment of patients chronically ... - Yahoo! News

Schering-Plough Provides Phase II Hepatitis C Drug Update  Apr 20, 2006
SCH 503034 is being evaluated in a Phase II study in combination with PEG-INTRON, or peginterferon alfa-2b, for the treatment of patients chronically infected ... - Therapeutics Daily (subscription)





Antibodies Neutralizing Peginterferon Alfa during Retreatment of ...  Mar 22, 2006
He had had no response to a 16-week course of treatment with peginterferon alfa-2b and ribavirin during . . . [Full Text of this Article]. - New England Journal of Medicine (subscription)

MIGENIX to Present at BIO 2006  Apr 6, 2006
I inhibitor for the treatment of chronic hepatitis C virus infections currently enrolling patients in combination with peginterferon alfa-2b with and without ... - Yahoo! News

MIGENIX Reports Third Quarter Fiscal Year 2006 Results  Mar 8, 2006
...of efficacy and safety in up to 60 patients randomly assigned to one of three treatment arms: (i) celgosivir plus peginterferon alfa-2b plus ribavirin (3-way ... - MSN Money

Valeant Pharmaceuticals Reports VISER1 Results for Viramidine(R) ...  Mar 21, 2006
...evaluated a fixed 600 mg BID dose of Viramidine to a weight-based 1,000/1,200 mg daily dose of ribavirin, both in combination with peginterferon alfa 2b. ... - Genetic Engineering News

Valeant Pharma's Viramidine Fails To Meet Efficacy Goal In ...  Mar 21, 2006
...evaluated a fixed 600 mg BID dose of Viramidine to a weight-based 1,000/1,200 mg daily dose of Ribavirin, both in combination with peginterferon alfa 2b. ... - Trading Markets

Valeant Pharma Says VISER1 Study Did Not Meet Non-Inferiority ...  Mar 21, 2006
...trial evaluated a fixed 600 mg BID dose of Viramidine to a weight-based 1,000/1,200 mg daily dose of ribavirin, both in combination with peginterferon alfa 2b. ... - Trading Markets

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional